A Current Practice Snapshot of Atopic Dermatitis Management: Where We Are and Where We Need to Be

This activity is designed for dermatologists, pediatricians, pediatric dermatologists, allergists, physician assistants, nurse practitioners, and nurses in dermatology and allergy actively treating patients with atopic dermatitis (AD).

Supported by educational grants from:

Pfizer Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals

Activity Information

Original Release Date: July 2019
Expiration Date: July 31, 2020
Estimated Time to Complete Activity: 0.25 hours

 

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.

The online post-test and evaluation can be accessed at https://tinyurl.com/ADInfoED

Inquiries about continuing medical education (CME) accreditation may be directed to Postgraduate Institute for Medicine (PIM) at www.pimed.com or (303) 799-1930.

Faculty

Linda F. Stein Gold, MD
Director of Dermatology Research
Division Head of Dermatology
Henry Ford Health System
Detroit, Michigan

Luz Fonacier, MD
Head of Allergy
Training Program Director
Winthrop University Hospital
Mineola, New York
Professor of Medicine
SUNY Stony Brook
Stony Brook, New York

Moise L. Levy, MD
Professor of Pediatrics and Medicine (Dermatology)
Dell Children’s Medical School
University of Texas, Austin
Clinical Professor of Dermatology and Pediatrics
Baylor College of Medicine
Pediatric/Adolescent Dermatology
Dell Children's Medical Center
Austin, Texas

Joint Provider Statement

In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education: The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Educational Needs

There is a wide variation in knowledge, competence, and practice among clinicians regarding the management of AD, especially in light of recent scientific advances and newly available therapies. To provide optimal care, specialists need foundational education regarding the etiology and pathophysiology of AD. To accurately assess their patients and decide on a course of treatment, they need awareness of available validated tools. They would further benefit from case-based AD education to facilitate application of the foundational learning into clinical practice.

Learning Objectives

At the conclusion of this program, participants should be better able to:

  • Describe the current theories of the pathophysiology of AD
  • Identify and apply the diagnostic criteria for AD
  • Employ strategies to manage patients with mild-to-moderate and moderate-to-severe AD

Disclosure Declarations

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Linda F. Stein Gold, MD, Speaker’s Bureau: Allergan, Celgene, Galderma, LEO, Novartis, Pfizer, Valeant; Consultant: AbbVie, Allergan, Celgene, Galderma, LEO, Medimetriks, Novartis, Pfizer, Promius, Valeant; Fees for Non-CME Services Received Directly from a Commercial Interest or Its Agent: AbbVie, Allergan, Celgene, Dermira, Galderma, La Roche- Posay, LEO, Medimetriks, Novan, Novartis, Pfizer, Promius, Sebela, Valeant; Contracted Research: Allergan, Aqua, Dermira, Galderma, LEO, Pfizer, Valeant.

Luz Fonacier, MD, Consultant: Regeneron/Sanofi; Fees for Non-CME Services Received Directly from a Commercial Interest or Its Agent: Regeneron/Sanofi; Contracted Research: Pfizer, Regeneron/Sanofi, and Shire to NYU Winthrop Hospital.

Moise L. Levy, MD, Consultant: Castle Creek Pharmaceuticals; Contracted Research: Amicus.

Staff and Planning Committee Members: The PIM planners and managers have nothing to disclose. The Global Academy for Medical Education planners and managers have nothing to disclose.

This CME/CE supplement was developed from interviews with the faculty. Dr Stein Gold, Dr Fonacier, and Dr Levy acknowledge the editorial assistance of Global Academy for Medical Education, Jamie Reiter, PhD, and Ron Schaumburg, medical writers, in the development of this supplement. Neither the editors of DERMATOLOGY NEWS nor the Editorial Advisory Board nor the reporting staff contributed to its content. The ideas and opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter, Global Academy for Medical Education, Postgraduate Institute for Medicine, or the Publisher.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Copyright © 2019 Global Academy for Medical Education, LLC, and Frontline Medical Communications. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, Frontline Medical Communications, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including claims related to the products, drugs, or services mentioned herein.